Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATXI Stock Price Chart Interactive Chart >
ATXI Price/Volume Stats
|Current price||$2.41||52-week high||$12.34|
|Prev. close||$2.72||52-week low||$2.22|
|Day high||$2.77||Avg. volume||310,966|
|50-day MA||$4.49||Dividend yield||N/A|
|200-day MA||$5.77||Market Cap||40.36M|
Avenue Therapeutics, Inc. (ATXI) Company Bio
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.
ATXI Latest News Stream
|Loading, please wait...|
ATXI Latest Social Stream
View Full ATXI Social Stream
Latest ATXI News From Around the Web
Below are the latest news stories about Avenue Therapeutics Inc that investors may wish to consider to help them evaluate ATXI as an investment opportunity.
Good morning, investors!
We're starting off the week right with a collection of the biggest pre-market stock movers for Monday that investors need to know about.
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. (“Avenue” or the “Company”) (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Avenue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 13, 2021, Avenue issued a press release “announc[ing] that the U.S. Food and Drug Administration (‘FDA’) was still reviewing its New Drug Application (‘NDA’) for IV tramadol and had not provided a decision regarding the NDA.” The Company’s resubmitted NDA for the treatment, which ...
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
ATXI Price Returns